• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

L-dopa therapy combined with peripheral decarboxylase inhibitor (MK-486) in Parkinsonism.

作者信息

Ohmoto T, Kishikawa H

出版信息

Folia Psychiatr Neurol Jpn. 1975;29(1):1-12. doi: 10.1111/j.1440-1819.1975.tb02318.x.

DOI:10.1111/j.1440-1819.1975.tb02318.x
PMID:1158313
Abstract

Eighteen patients with parkinsonism were treated with a combination of L-dopa and peripheral decarboxylase inhibitor, L-alphahydrazinomethyldopa (MK-486). Modification of L-dopa effect by MK-486 was also studied in parkinsonian patients as well as in cats. (1) Concentrations of dopa and dopamine in plasma and brain were measured in cats following intraperitoneal injection of L-dopa alone (100 mg/kg) or combined with MK-486 (10 mg/kg). Dopa levels in plasma and brain in the combination with MK-486 were three times as high as in L-dopa alone. Dopamine levels in caudate nucleus and putamen were increased nearly fourfold with the combination. (2) Plasma dopa and dopamine levels were measured in parkinsonian patients. Clinical pharmacological studies disclosed that a 1 : 10 ratio of MK-486 to L-dopa in dosage was preferable. (3) Maximum plasma dopa levels with the combination were four times those following L-dopa alone. Plasma dopa sustained a high level over a period of five hours. MK-486 markedly reduced plasma levels of dopamine. (4) There was no significant difference in dopa and dopamine levels in cerebrospinal fluid between L-dopa alone and a combination of MK-486, but dopamine levels in the CSF were still high at four hours after the combination of MK-486. (5) In clinical studies of eighteen patients with parkinsonism, the effectiveness of the combination therapy (mean dosage of L-dopa: 750 mg/day) was observed in all cases. Marked improvement was noted in 10 cases out of 15 (67%) with akinesia, in 12 cases out of 17 (71%) with rigidity and in six cases out of 14 (43%) with tremor. Maximum plasma dopa levels were higher in those cases with marked improvement, and were highest in patients with diskinesias as a side effect. (6) An addition of vitamin B6 did not show adverse effects. (7) Transient nausea and vomiting as a side effect, less severe than those experienced with L-dopa alone, were noted in five cases (28%). Dyskinesias in extremities, face, mouth and tongue were observed in six cases (33%). These dyskinesias were seen in a high percentage of cases with marked improvement and were never observed in the extremities contralateral to the side of thalamotomy.

摘要

相似文献

1
L-dopa therapy combined with peripheral decarboxylase inhibitor (MK-486) in Parkinsonism.
Folia Psychiatr Neurol Jpn. 1975;29(1):1-12. doi: 10.1111/j.1440-1819.1975.tb02318.x.
2
[Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine].左旋多巴与外周多巴脱羧酶抑制剂联合治疗帕金森病——13例临床病程及血清/多巴和多巴胺水平
Rinsho Shinkeigaku. 1976 Jul 1;16(7):511-9.
3
Treatment of idiopathic parkinsonism with L-dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of L-dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa.在有无脱羧酶抑制剂的情况下用左旋多巴治疗特发性帕金森病:对血浆中左旋多巴、多巴脱羧酶、儿茶酚胺和3 - O - 甲基多巴水平的影响
J Neurol. 1989 May;236(4):223-30. doi: 10.1007/BF00314504.
4
L-dopa-carbidopa: combined therapy for the treatment of Parkinson's disease.左旋多巴-卡比多巴:用于治疗帕金森病的联合疗法。
Dis Nerv Syst. 1976 Mar;37(3):123-5.
5
Treatment of parkinsonism with l-dopa and a decarboxylase inhibitor. An electrophysiological and clinical study.左旋多巴与脱羧酶抑制剂治疗帕金森综合征:一项电生理与临床研究。
Eur Neurol. 1975;13(4):339-49. doi: 10.1159/000114688.
6
Induction of aromatic-L-amino acid decarboxylase by decarboxylase inhibitors in idiopathic parkinsonism.
Ann Neurol. 1989 Jun;25(6):624-8. doi: 10.1002/ana.410250616.
7
Controlled-release levodopa/benserazide (Madopar HBS): clinical observations and levodopa and dopamine plasma concentrations in fluctuating parkinsonian patients.控释左旋多巴/苄丝肼(美多芭HBS):波动性帕金森病患者的临床观察及左旋多巴和多巴胺血浆浓度
J Neurol. 1990 Feb;237(1):24-8. doi: 10.1007/BF00319663.
8
Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone in Parkinson's disease.多巴脱羧酶抑制剂(卡比多巴)联合左旋多巴与单用左旋多巴治疗帕金森病的比较。
Neurology. 1975 Oct;25(10):911-6. doi: 10.1212/wnl.25.10.911.
9
Levodopa combined with MK 486 (L-alpha methyldopahydrazine)--a peripheral decarboxylase inhibitor in Parkinson's disease.左旋多巴与MK 486(L-α-甲基多巴肼)联合应用——一种帕金森病外周脱羧酶抑制剂。
Med J Aust. 1974 Mar 23;1(12):429-32.
10
Study of deterioration in long-term treatment of parkinsonism with L-dopa plus decarboxylase inhibitor.左旋多巴加脱羧酶抑制剂长期治疗帕金森病的疗效减退研究。
J Neural Transm. 1976;38(3-4):249-58. doi: 10.1007/BF01249442.

引用本文的文献

1
Human equivalent doses of L-DOPA rescues retinal morphology and visual function in a murine model of albinism.L-DOPA 的人体等效剂量可挽救白化病小鼠模型的视网膜形态和视觉功能。
Sci Rep. 2023 Oct 11;13(1):17173. doi: 10.1038/s41598-023-44373-3.
2
Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.左旋多巴与脱羧酶抑制剂:其临床药理学及在帕金森病治疗中的应用综述
Drugs. 1976;11(5):329-77. doi: 10.2165/00003495-197611050-00001.